The hygiene hypothesis, suggesting that low exposure to pathogens early in life can increase the risk for immune-mediated diseases, has been proposed as an explanation for the increase in incidence of allergy and autoimmune diseases in industrialized countries during the last decades. Several aspects of the hygiene hypothesis have been related to MS. Already in 1966, the risk of MS was suggested to be higher in individuals with high hygienic standard during childhood. Further, an episode of infectious mononucleosis is an independent risk factor for MS and can be regarded as an indicator of low exposure to pathogens early in life, as infection with Epstein-Barr virus often is asymptomatic when it occurs in young children. Conflicting results have been reported regarding number of siblings, attendance in a day care center and exposure to animals during childhood in relation to MS risk, but common childhood infections and vaccinations do not seem to influence the risk of MS. In line with the hygiene hypothesis, two large meta-analyses have recently shown that infection with Helicobacter pylori is negatively correlated with MS. Moreover, a protective influence of helminth infection on MS has been observed in several, small clinical studies, but more knowledge is needed before a potential role of helminth-derived therapy in MS is determined. Also, it has been hypothesized that infection with the parasite
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Helicobacter pylori is negatively correlated with MS. Moreover, a protective influence of helminth infection on MS has been observed in several, small clinical studies, but more knowledge is needed before a potential role of helminth-derived therapy in MS is determined. Also, it has been hypothesized that infection with the parasite Toxoplasma gondii could be protective against MS.
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| GENERAL BACKGROUND OF THE HYGIENE HYPOTHESIS
The hygiene hypothesis, suggesting that low exposure to pathogens early in life could lead to a greater risk of immune-mediated diseases later in life, has been proposed as an explanation for the increased incidences of allergy and autoimmune diseases observed in industrialized countries during the last decades. [1] [2] [3] The hygiene hypothesis was first postulated in 1989 by Strachan who observed that the risk of allergic rhinitis was inversely linked to birth order and family size and thereby suggested that infections within households in early childhood could play a role in preventing allergic rhinitis. 1, 4 The hypothesis was further supported by epidemiological data demonstrating an inverse relationship between infectious diseases and immune-mediated diseases, such as allergy and autoimmune diseases in industrialized countries. 2 An imbalance between T-helper (Th) 1 cells and Th2 cells was initially proposed as an immunological explanation for the hygiene hypothesis. 5 The background for this was the understanding that Th2 cells are central in the allergen sensitization process and that Th1 immune responses are stimulated by infections with intracellular bacteria and viruses and lead to suppression of Th2 cytokine activity. 6 Later, additional T-cell phenotypes such as T-regulatory cells and Th17 and innate cell types and cytokines have been increasingly acknowledged to play important roles in the pathogenesis of immune-mediated diseases. Hence, the immunological explanation of the hygiene hypothesis has been modified to consider a disrupted balance between many adaptive and innate immune cell populations. 5 Notably, some important modifications and extensions of the hygiene hypothesis have been made during the last years. It has been argued that that term "hygiene hypothesis" is misleading and that "microbial deprivation hypothesis" would be a more correct term. 7 Others have underlined that the term "hygiene" in the hygiene hypothesis refers to all changes in lifestyle corresponding to "Westernization" 
| THE HYGIENE HYPOTHESIS IN RELATION TO MS
Multiple sclerosis (MS) is an immune-mediated, inflammatory disease in the central nervous system that leads to demyelination and neurodegeneration. 9 The CD4 + T-cell subsets Th1 and Th17 seem to be the major cells inducing inflammation and subsequently neurodegeneration, whereas CD8 + T cells are more directly involved in demyelination and axonal degeneration. 
| The Epstein-Barr virus variant of the hygiene hypothesis in MS
An episode of infectious mononucleosis (IM), the clinical manifestation of Epstein-Barr virus (EBV) infection, is an independent risk factor for MS. 13 An episode of IM can be regarded as an indicator of low exposure to pathogens early in life, as EBV infections often are asymptomatic in young children. It has been argued that this is in line with the hygiene hypothesis. 14 On the other hand, the fact that MS risk is extremely low in EBV-negative individuals 15 
| Infection with Toxoplasma gondii in relation to MS
Toxoplasma gondii is a protozoan parasite that can cause toxoplasmosis in humans. The infection is often chronic and lifelong and can induce anti-inflammatory processes in the host. 28 Toxoplasma gondii is primarily hosted in cats, but can also be hosted in other animals such as mice, rabbits, and dogs. A protective effect of cat ownership on MS has been reported in some studies. 29 
| Do parasitic helminths have a therapeutic potential in MS?
Helminths are parasitic worms with immune-modulatory abilities which exert their immunoregulatory actions by modulating cells of both the innate and adaptive immune system. 8, 36 It has been hypothesized that helminths could have a protective influence on MS through downmodulation of inflammatory responses and enhancing immune regulation. 37 This has been studied both in animal models and in observational studies. In mice with EAE, the disease severity was reduced after helminth ova immunization. 38 A prospective study comparing 12 MS patients with various helminth infections to 12 non-helminth-infected MS patients for 4.5 years reported that the infected individuals had significantly fewer relapses and lower MRI activity. 39 A follow-up study from the same group demonstrated that after antihelminthic treatment, the clinical and radiological activity increased to levels observed in uninfected MS patients. 40 Promising results from studies in mouse models and exploratory clinical trials with helminth-derived therapy in autoimmune diseases have led to several clinical trials in various autoimmune diseases (eg, inflammatory bowel disease, rheumatoid arthritis, psoriasis, celiac disease, and MS). Results not yet published.
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human hookworm Necator americanus. 42 The eggs of T. suis hatch after ingestion, but the worms only colonize the gut for a few weeks.
Therefore, the treatment is repeated every second week. In contrast, larvae of the hookworm Necator americanus are given percutaneously and migrate to the small intestine where they cause long-lasting infections with possibly side effects such as anemia and gastrointestinal symptoms. 42 No major safety concerns have yet been observed after human helminth therapy. 5, 41 Notably, two phase 2 trials in patients with Crohn's disease treated with T. suis ova did not meet its primary endpoints and were discontinued.
42 Table 1 gives an overview of the completed and ongoing clinical studies of helminth-derived therapy in MS. In a pilot study published in 2011, five treatment-naive patients with relapsing-remitting MS (RRMS) were given 2500 T. suis ova orally every second week for 12
weeks. 43 The mean number of new gadolinium-enhancing MRI lesions fell from 6.6 at baseline to 2.0 at the end of T. suis ova administration.
Two months after the treatment was discontinued, the mean number of gadolinium-enhancing MRI lesions was 5.8. Also, an increase in the serum level of the Th2-associated cytokines IL-4 and IL-10 was noted in four of the subjects. In a study by Benzel and coworkers, four patients with secondary progressive MS (SPMS) were given T. suis ova during 6 months, and a slight downregulation of the Th1-associated cytokine pattern and an increase in Th2-associated cytokines were observed, indicating that therapy with T. suis ova has a possible immunomodulatory effect in patients with MS. 44 In contrast to the observations in the previous studies, no beneficial clinical or immunological effects could be detected in a Danish study including 10 patients with RRMS who were given T. suis ova for 12 weeks. 45 In 2013, a study protocol for a randomized controlled trial (RCT) aiming to investigate helminth-derived therapy in patients with MS was published. 46 In this study, 50 patients with RRMS or CIS not undergoing any standard MS therapies will be randomized to T. suis ova or placebo. The authors state that the safety profile, tolerability and effect on disease activity of T. suis ova in MS will be investigated in addition to the immune responses in the participants. Moreover, in another ongoing RCT the investigators are planning to apply hookworm larvae solution or placebo dermally in 72 patients with RRMS and compare the degree of disease activity. 41 No results are yet published from these RCTs, but it is hoped that the observations in these studies will increase the knowledge of potential effects of helminth-derived therapy in MS.
| CONCLUSIONS
The hygiene hypothesis could to some extent be relevant in MS, but presumably only as one factor among several others in the understand- 
